Syros

Syros Announces Clinical Updates and 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Disease, MDS, Phenotype, Toxicity, RARA, Roche, AML, Arsenic trioxide, Safety, Azacitidine, AUC, Pancreatic cancer, SELECT, Venetoclax, APL, BRAF, ASH, Partnership, Lymphatic system, Patient, Society, Syros, Pharmaceutical industry, Cmax

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023.
  • Syros currently has over 75 clinical sites open for recruitment in 12 countries.
  • Syros expects to complete patient enrollment in SELECT-MDS-1 in the fourth quarter of 2023, with data to follow in the third quarter of 2024.
  • Syros is developing SY-2101, a novel oral form of arsenic trioxide (ATO) for the treatment of newly diagnosed APL patients.

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 23, 2022
Finance, Health, Genetics, Professional Services, Pharmaceutical, RSU, Gene, Employment, Pharmaceutical industry, Syros

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 14,200 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 14,200 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros.
  • These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The awards were granted on December 22, 2022, and vest as to one-quarter of the shares on December 31, 2023 and as to an additional one-quarter of the shares at the end of each successive year thereafter, subject to the employee’s continued service with Syros.
  • These awards are subject to the terms and conditions of a restricted stock unit agreement covering the award and Syros’ 2022 Inducement Stock Incentive Plan.

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS

Retrieved on: 
Monday, December 12, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Genome, Security (finance), ORR, Observation, Freedom, Azacitidine, Venetoclax, Institut Gustave Roussy, Patient, CR, Toxicity, Tamibarotene, Annual report, Compte rendu, Biology, Aplastic anemia, Arsenic trioxide, Myelodysplastic syndrome, Government, COVID-19, AML, Clinical trial, Safety, CDK7, Workforce, MDS, Acute myeloid leukemia, Gene, AES, RARA, Acute promyelocytic leukemia, Pharmaceutical industry, Syros

These findings support Syros ongoing evaluation of tamibarotene for the treatment of AML and myelodysplastic syndrome (MDS) patients with RARA overexpression.

Key Points: 
  • These findings support Syros ongoing evaluation of tamibarotene for the treatment of AML and myelodysplastic syndrome (MDS) patients with RARA overexpression.
  • The biomarker test successfully identified AML patients positive for RARA overexpression who were enriched for response to tamibarotene and azacitidine relative to those patients who were negative for RARA overexpression.
  • This observation further demonstrates that the activity of tamibarotene is dependent on the biology of RARA overexpression.
  • Based on RARA expression levels, each patient was classified as positive for RARA overexpression (22 patients) or negative for RARA overexpression (29 patients).

Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Retrieved on: 
Saturday, December 10, 2022
Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Genome, Pneumonia, University of Colorado School of Medicine, Society, Toxicity, Aplastic anemia, Disease, Government, Patient, COVID-19, AML, ELN, Gene, Anxiety, Phenotype, Associate, Diagnosis, Rash, Șaeș, DiNardo, Arsenic trioxide, Clinical trial, University, Toxic leukoencephalopathy, Acute promyelocytic leukemia, Security (finance), Webcast, The New England Journal of Medicine, Leukemia, Cough, CRi, European, Workforce, ASH, RARA, IWG, Freedom, Salvage therapy, CR, Elevated railway, Annual report, Compte rendu, Blood, Safety, CDK7, Acute myeloid leukemia, AES, Febrile neutropenia, Pharmaceutical industry, Medical device, Azacitidine, Syros, Venetoclax

As of October 13, 2022, eight newly diagnosed, unfit, RARA-positive patients had been enrolled in the trial, including six who were evaluable for response.

Key Points: 
  • As of October 13, 2022, eight newly diagnosed, unfit, RARA-positive patients had been enrolled in the trial, including six who were evaluable for response.
  • - Tamibarotene in combination with venetoclax and azacitidine administered at approved doses showed no evidence of increased toxicity relative to the doublet combination of venetoclax and azacitidine.
  • This includes rates of myelosuppression, which were comparable to reports with venetoclax and azacitidine in this population.
  • The randomized portion is expected to initiate in Q1 2023, with data expected in 2023 or 2024.

Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10

Retrieved on: 
Monday, December 5, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Genome, Syros, Webcast, University of Colorado School of Medicine, Leukemia, Society, Patient, Arsenic trioxide, Associate, AML, Clinical trial, University, Safety, CDK7, Acute myeloid leukemia, Gene, ASH, RARA, Acute promyelocytic leukemia, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML).

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML).
  • The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m.
  • In addition, a live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com .
  • Initial data from the SELECT-AML-1 trial will also be presented on Saturday, December 10, 2022 in a poster session at the 64th American Society of Hematology (ASH) Annual Meeting.

Syros to Participate at Piper Sandler 34th Annual Healthcare Conference

Retrieved on: 
Tuesday, November 22, 2022
Health, Biometrics, Genetics, Other Health, Pharmaceutical, Biotechnology, Arsenic trioxide, Syros, RARA, Lotte New York Palace Hotel, Acute myeloid leukemia, Conference, Madison Avenue, Piper Sandler Companies, CDK7, Gene, Acute promyelocytic leukemia, Webcast, Patient, Genome, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference.
  • An archived replay of the webcast will be available for approximately 30 days following the presentation.
  • Syros is redefining the power of small molecules to control the expression of genes.
  • Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Retrieved on: 
Monday, November 7, 2022
Health, Genetics, Science, Pharmaceutical, Research, Genome, Arsenic trioxide, Syros, RARA, Investor, Webcast, Gene, Patient, Acute myeloid leukemia, Acute promyelocytic leukemia, CDK7, NASDAQ, Pharmaceutical industry

ET on Monday, November 14, 2022 to report its third quarter 2022 financial results and provide a corporate update.

Key Points: 
  • ET on Monday, November 14, 2022 to report its third quarter 2022 financial results and provide a corporate update.
  • To access the live conference call, please register using the conference link here .
  • While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.
  • A webcast of the call will be available on the Investors & Media section of the Syros website at www.syros.com .

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 4, 2022
General Health, Other Health, Health, Genetics, Clinical Trials, Arsenic trioxide, Acute myeloid leukemia, CDK7, RARA, Employment, Genome, NASDAQ, RSU, Gene, Patient, Acute promyelocytic leukemia, Pharmaceutical industry, Syros

These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The awards were granted on October 31, 2022 and vest in equal annual installments over a period of four years, subject to the employees continued service with Syros.
  • These awards are subject to the terms and conditions of a restricted stock unit agreement covering the award and Syros 2022 Inducement Stock Incentive Plan.
  • Syros is redefining the power of small molecules to control the expression of genes.

Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Arsenic trioxide, Azacitidine, Society, Safety, ASH, Acute myeloid leukemia, Transplant, CDK7, RARA, NASDAQ, Genome, Syros, Gene, AML, Patient, Acute promyelocytic leukemia, Cellular, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, LA.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, LA.
  • The SELECT-AML-1 trial is evaluating tamibarotene, Syros first-in-class selective retinoic acid receptor alpha (RAR) agonist, in combination with venetoclax and azacitidine in patients with newly diagnosed, unfit acute myeloid leukemia (AML) with RARA gene overexpression.
  • Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
    Syros is redefining the power of small molecules to control the expression of genes.
  • Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, October 5, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, LinkedIn, RSU, Acute myeloid leukemia, Employment, Arsenic trioxide, Patient, RARA, Twitter, CDK7, Nasdaq, Genome, Gene, Acute promyelocytic leukemia, Pharmaceutical industry, Syros

Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 1,260 shares of Syros common stock to one newly hired employee in connection with the employees commencement of employment with Syros.

Key Points: 
  • Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 1,260 shares of Syros common stock to one newly hired employee in connection with the employees commencement of employment with Syros.
  • These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Syros is redefining the power of small molecules to control the expression of genes.
  • Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.